ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Green Cross (006280.KO)
Green Cross stock price today, ATLAS forecast and fair value
Healthcare · Drug Manufacturers - Specialty & Generic · Korea Exchange (KOSPI) · South Korea
₩129,100▼ -0.39%
Prices as of Oct 27, 2026 · KRW
Chance of rising in 1 month
50%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Green Cross in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Green Cross
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Green Cross a 50% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between ₩120,711 and ₩137,954; in 9 out of 10, between ₩107,237 and ₩155,288. Estimated annual volatility is 38%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- ₩1.4T
- Market cap (USD)
- $1.1B
- Dividend yield
- 1.13%
- 52-week high
- ₩183,800
- 52-week low
- ₩105,900
- Revenue (12 months)
- ₩2.0T
- Gross margin
- 26.3%
- Operating margin
- 0.4%
- Net margin
- -2.5%
- Beta
- 0.68
What this means
ATLAS does not publish a fair value for 006280.KO right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks 006280.KO has traded between ₩105,900 and ₩183,800. Today it is 29.8% below that high and 22% above its low.
Its beta is 0.68: it tends to move less than the market.
About the company
GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea, India, Taiwan, Japan, China, Malaysia, and internationally.
Want to see everything about Green Cross?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Green Cross do?
GC Biopharma Corp., a biopharmaceutical company, develops and sells pharmaceutical drugs in South Korea, India, Taiwan, Japan, China, Malaysia, and internationally.
What is the chance 006280.KO goes up next month?
50%: close to a coin flip. In half of the simulated outcomes, 006280.KO ends the month between ₩120,711 and ₩137,954.
How big is Green Cross and what is its P/E ratio?
Green Cross's market capitalization is ₩1.4T. We do not show a P/E because it has no positive earnings to base one on.
Does Green Cross pay a dividend?
Yes. 006280.KO's current dividend yield is 1.13% at today's price (₩129,100).
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer